COVID-SEROINDEX Trademark

Trademark Overview


On Monday, August 3, 2020, a trademark application was filed for COVID-SEROINDEX with the United States Patent and Trademark Office. The USPTO has given the COVID-SEROINDEX trademark a serial number of 90089895. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 19, 2022. This trademark is owned by Kantaro Biosciences LLC. The COVID-SEROINDEX trademark is filed in the Chemical Products category with the following description:

Diagnostic agents, preparations and substances other than for medical or veterinary purposes; Diagnostic preparations and reagents for scientific or medical research use; Diagnostic preparations and reagents for clinical or medical laboratory use; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting and analyzing antibodies, enzymes, antigens, diseases, viruses and infections for scientific, laboratory or medical research use; Test kits consisting of diagnostic preparations, reagents, assays, solutions and buffers for clinical or medical laboratory testing and analysis of SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Test kits comprised of diagnostic preparations, reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens for use i...
covid-seroindex

General Information


Serial Number90089895
Word MarkCOVID-SEROINDEX
Filing DateMonday, August 3, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 19, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 21, 2021

Trademark Statements


Goods and ServicesDiagnostic agents, preparations and substances other than for medical or veterinary purposes; Diagnostic preparations and reagents for scientific or medical research use; Diagnostic preparations and reagents for clinical or medical laboratory use; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting and analyzing antibodies, enzymes, antigens, diseases, viruses and infections for scientific, laboratory or medical research use; Test kits consisting of diagnostic preparations, reagents, assays, solutions and buffers for clinical or medical laboratory testing and analysis of SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Test kits comprised of diagnostic preparations, reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens for use in infection, virus and disease detection for scientific or medical research use; Diagnostic preparations for scientific or research purposes related to vaccines in the fields of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Diagnostic assays, media, solutions and buffers for clinical use; Diagnostic agents for carrying out serologic tests for clinical purposes; Diagnostic reagents for serologic tests of infections for clinical purposes; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting antibodies, enzymes, antigens, diseases, viruses and infections for clinical and research purposes; Diagnostic preparations for clinical purposes for detecting the presence of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; all the foregoing related to the detection, diagnosis, testing, prevention and/or treatment of SARS-CoV-2, COVID-19 and antibodies, antigens, diseases, illnesses, viruses, disorders and/or infections related to SARS-CoV-2 or COVID-19

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateTuesday, September 1, 2020
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKantaro Biosciences LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10036

Party NameKantaro Biosciences LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNew York, NY 10036

Trademark Events


Event DateEvent Description
Monday, September 19, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, September 19, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, February 15, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 21, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 21, 2021PUBLISHED FOR OPPOSITION
Wednesday, December 1, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sunday, November 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 27, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 20, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 20, 2021NON-FINAL ACTION E-MAILED
Saturday, March 20, 2021NON-FINAL ACTION WRITTEN
Friday, February 26, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 26, 2021NON-FINAL ACTION E-MAILED
Friday, February 26, 2021NON-FINAL ACTION WRITTEN
Wednesday, February 10, 2021ASSIGNED TO EXAMINER
Tuesday, September 1, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, August 6, 2020NEW APPLICATION ENTERED IN TRAM